Retatrutide, a novel dual activator of the GLP-1 binding site and glucose-dependent insulinotropic polypeptide (GIP) receptor , is exhibiting promising results in early patient assessments . Recent inquiry suggests that retatrutide may offer substantial advantages for individuals with diabetes , particularly regarding weight reduction and glycemic